A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus

Trial Profile

A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 May 2017

At a glance

  • Drugs Forigerimod (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Registrational; Therapeutic Use
  • Acronyms LUPUZOR
  • Sponsors ImmuPharma
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 17 May 2017 According to an ImmuPharma media release, at end-April 2017 all 200 patients have passed the 3 months stage, over 80% of patients (166) have passed 6 months, 49 patients passed the 9 months stage and 28 patients have passed the full 12 months in this study. Top line results are expected in Q1 2018.
    • 24 Jan 2017 Planned End Date changed from 1 Dec 2017 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top